GlobeNewsWire
03 Aug 2026, 10:35 UTC · 1h ago
Supernus Announces Second Quarter 2026 Financial Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
03 Aug 2026, 10:35 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Supernus Pharmaceuticals has entered into an agreement to merge with Indivior Pharmaceuticals in a merger of equals. — Mergers typically trigger significant price action due to changes in scale, synergy potential, and fundamental company valuation.
+0.60Supernus is raising its full year 2026 financial guidance. — Upward revisions to financial guidance generally signal stronger-than-expected growth and positive momentum for the stock.
+0.40The company reported continued strength and sustained momentum in its growth products for the first half of 2026. — Positive operational updates confirm stability in the core business, though less impactful than a merger or guidance raise.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported strength in growth products, raised its full-year 2026 financial guidance, and announced a strategic merger.
The company entered into a merger of equals with Supernus to create a well-positioned CNS company with increased scale.
Mentioned as a collaborator providing revenue streams via ZURZUVAE sales.
[mutual] Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into an agreement to merge in a merger of equals.
[a_to_b] The text references the closing of Biogen's acquisition of Sage Therapeutics.
[mutual] Supernus maintains a collaboration agreement with Biogen for the sale of ZURZUVAE.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
